Daniel T. Scavilla - 02 Jul 2021 Form 4 Insider Report for GLOBUS MEDICAL INC (GMED)

Role
EVP, Chief Commercial Officer
Signature
/s/ Kelly G. Huller, Attorney-in-Fact
Issuer symbol
GMED
Transactions as of
02 Jul 2021
Transactions value $
-$5,251,724
Form type
4
Filing time
07 Jul 2021, 16:46:35 UTC
Next filing
31 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GMED Class A Common Stock Options Exercise $1.28M +50K $25.52 50K 02 Jul 2021 Direct
transaction GMED Class A Common Stock Options Exercise $1.31M +50K +100% $26.27 100K 02 Jul 2021 Direct
transaction GMED Class A Common Stock Sale -$7.81M -99.6K -99.6% $78.41 400 02 Jul 2021 Direct F1, F2
transaction GMED Class A Common Stock Sale -$31.6K -400 -100% $78.97 0 02 Jul 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GMED Stock Option (Right to buy Class A Common Stock) Options Exercise $0 -50K -100% $0.00* 0 02 Jul 2021 Class A Common Stock 50K $25.52 Direct F3
transaction GMED Stock Option (Right to Buy Class A Common Stock) Options Exercise $0 -50K -62.5% $0.00 30K 02 Jul 2021 Class A Common Stock 50K $26.27 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.83 to $78.69, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3 These options were granted on January 25, 2016, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2017, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
F4 These options were granted on January 30, 2017, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2018, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.